Factor VIII von Willebrand factor antigen levels correlate with symptom severity in patients with Raynaud's phenomenon

C. S. Lau, M. McLaren, J. J. F. Belch

    Research output: Contribution to journalArticle

    18 Citations (Scopus)

    Abstract

    We have previously documented raised levels of factor VIII von Willebrand factor antigen (FVIII vWF Ag), an endothelial product, in patients with vascular diseases and suggested that levels of this relate to disease activity. No one has yet investigated patients with Raynaud's phenomenon (RP) alone to see if the severity of vasospastic attacks relates to FVIII vWF Ag.
    We studied 22 patients with RP. None of these patients fulfilled diagnostic criteria for a connective tissue disease but all had severe symptoms which warranted referral to hospital. We measured the FVIII vWF Ag and the procoagulant factor VIII (FVIII:c) levels in these patients. FVIII:c is not an endothelial product and is released by different mechanisms, thus it forms an active control to FVIII vWF Ag. FVIII vWF Ag measurements were carried out using the Laurell method and FVIII:c was assessed using the technique described by Nilsson. Patients were asked to complete diaries over a 2-week winter period. The frequency and duration of all Raynaud's attacks were recorded. There were significant positive correlations between FVIII vWF Ag and the total number and duration of RP attacks over the 2-week period (P < 0.005, r = 0.67 and P < 0.05, r = 0.40, respectively; Spearman's rank correlation). No correlation was found between levels of FVIII:c and the same clinical parameters.
    It has been suggested that patients with clinical evidence of vascular damage have elevated plasma levels of FVIII vWF Ag. Our present study has demonstrated correlations between FVIII vWF Ag levels and the clinical severity of vasospasm in patients with RP. Whether severe blood vessel spasm causes an increase in FVIII vWF Ag release or patients with blood vessel damage have more severe attacks of RP is not yet clear; however, FVIII vWF Ag levels may serve as a marker of
    disease activity in these patients.
    Original languageEnglish
    Pages (from-to)433-436
    Number of pages4
    JournalBritish Journal of Rheumatology
    Volume30
    Issue number6
    DOIs
    Publication statusPublished - Dec 1991

    Fingerprint

    Raynaud Disease
    Blood Vessels
    Von Willebrand antigen
    factor VIII, von Willebrand factor drug combination
    Connective Tissue Diseases
    Factor VIII
    Spasm
    Vascular Diseases
    Referral and Consultation

    Cite this

    @article{cfad687ce7d74e28abebd209ed025d51,
    title = "Factor VIII von Willebrand factor antigen levels correlate with symptom severity in patients with Raynaud's phenomenon",
    abstract = "We have previously documented raised levels of factor VIII von Willebrand factor antigen (FVIII vWF Ag), an endothelial product, in patients with vascular diseases and suggested that levels of this relate to disease activity. No one has yet investigated patients with Raynaud's phenomenon (RP) alone to see if the severity of vasospastic attacks relates to FVIII vWF Ag. We studied 22 patients with RP. None of these patients fulfilled diagnostic criteria for a connective tissue disease but all had severe symptoms which warranted referral to hospital. We measured the FVIII vWF Ag and the procoagulant factor VIII (FVIII:c) levels in these patients. FVIII:c is not an endothelial product and is released by different mechanisms, thus it forms an active control to FVIII vWF Ag. FVIII vWF Ag measurements were carried out using the Laurell method and FVIII:c was assessed using the technique described by Nilsson. Patients were asked to complete diaries over a 2-week winter period. The frequency and duration of all Raynaud's attacks were recorded. There were significant positive correlations between FVIII vWF Ag and the total number and duration of RP attacks over the 2-week period (P < 0.005, r = 0.67 and P < 0.05, r = 0.40, respectively; Spearman's rank correlation). No correlation was found between levels of FVIII:c and the same clinical parameters. It has been suggested that patients with clinical evidence of vascular damage have elevated plasma levels of FVIII vWF Ag. Our present study has demonstrated correlations between FVIII vWF Ag levels and the clinical severity of vasospasm in patients with RP. Whether severe blood vessel spasm causes an increase in FVIII vWF Ag release or patients with blood vessel damage have more severe attacks of RP is not yet clear; however, FVIII vWF Ag levels may serve as a marker ofdisease activity in these patients.",
    author = "Lau, {C. S.} and M. McLaren and Belch, {J. J. F.}",
    year = "1991",
    month = "12",
    doi = "10.1093/rheumatology/30.6.433",
    language = "English",
    volume = "30",
    pages = "433--436",
    journal = "British Journal of Rheumatology",
    issn = "0263-7103",
    publisher = "Oxford University Press",
    number = "6",

    }

    Factor VIII von Willebrand factor antigen levels correlate with symptom severity in patients with Raynaud's phenomenon. / Lau, C. S.; McLaren, M.; Belch, J. J. F.

    In: British Journal of Rheumatology, Vol. 30, No. 6, 12.1991, p. 433-436.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Factor VIII von Willebrand factor antigen levels correlate with symptom severity in patients with Raynaud's phenomenon

    AU - Lau, C. S.

    AU - McLaren, M.

    AU - Belch, J. J. F.

    PY - 1991/12

    Y1 - 1991/12

    N2 - We have previously documented raised levels of factor VIII von Willebrand factor antigen (FVIII vWF Ag), an endothelial product, in patients with vascular diseases and suggested that levels of this relate to disease activity. No one has yet investigated patients with Raynaud's phenomenon (RP) alone to see if the severity of vasospastic attacks relates to FVIII vWF Ag. We studied 22 patients with RP. None of these patients fulfilled diagnostic criteria for a connective tissue disease but all had severe symptoms which warranted referral to hospital. We measured the FVIII vWF Ag and the procoagulant factor VIII (FVIII:c) levels in these patients. FVIII:c is not an endothelial product and is released by different mechanisms, thus it forms an active control to FVIII vWF Ag. FVIII vWF Ag measurements were carried out using the Laurell method and FVIII:c was assessed using the technique described by Nilsson. Patients were asked to complete diaries over a 2-week winter period. The frequency and duration of all Raynaud's attacks were recorded. There were significant positive correlations between FVIII vWF Ag and the total number and duration of RP attacks over the 2-week period (P < 0.005, r = 0.67 and P < 0.05, r = 0.40, respectively; Spearman's rank correlation). No correlation was found between levels of FVIII:c and the same clinical parameters. It has been suggested that patients with clinical evidence of vascular damage have elevated plasma levels of FVIII vWF Ag. Our present study has demonstrated correlations between FVIII vWF Ag levels and the clinical severity of vasospasm in patients with RP. Whether severe blood vessel spasm causes an increase in FVIII vWF Ag release or patients with blood vessel damage have more severe attacks of RP is not yet clear; however, FVIII vWF Ag levels may serve as a marker ofdisease activity in these patients.

    AB - We have previously documented raised levels of factor VIII von Willebrand factor antigen (FVIII vWF Ag), an endothelial product, in patients with vascular diseases and suggested that levels of this relate to disease activity. No one has yet investigated patients with Raynaud's phenomenon (RP) alone to see if the severity of vasospastic attacks relates to FVIII vWF Ag. We studied 22 patients with RP. None of these patients fulfilled diagnostic criteria for a connective tissue disease but all had severe symptoms which warranted referral to hospital. We measured the FVIII vWF Ag and the procoagulant factor VIII (FVIII:c) levels in these patients. FVIII:c is not an endothelial product and is released by different mechanisms, thus it forms an active control to FVIII vWF Ag. FVIII vWF Ag measurements were carried out using the Laurell method and FVIII:c was assessed using the technique described by Nilsson. Patients were asked to complete diaries over a 2-week winter period. The frequency and duration of all Raynaud's attacks were recorded. There were significant positive correlations between FVIII vWF Ag and the total number and duration of RP attacks over the 2-week period (P < 0.005, r = 0.67 and P < 0.05, r = 0.40, respectively; Spearman's rank correlation). No correlation was found between levels of FVIII:c and the same clinical parameters. It has been suggested that patients with clinical evidence of vascular damage have elevated plasma levels of FVIII vWF Ag. Our present study has demonstrated correlations between FVIII vWF Ag levels and the clinical severity of vasospasm in patients with RP. Whether severe blood vessel spasm causes an increase in FVIII vWF Ag release or patients with blood vessel damage have more severe attacks of RP is not yet clear; however, FVIII vWF Ag levels may serve as a marker ofdisease activity in these patients.

    U2 - 10.1093/rheumatology/30.6.433

    DO - 10.1093/rheumatology/30.6.433

    M3 - Article

    C2 - 1747698

    VL - 30

    SP - 433

    EP - 436

    JO - British Journal of Rheumatology

    JF - British Journal of Rheumatology

    SN - 0263-7103

    IS - 6

    ER -